“Why Trump’s Push for U.S.-Made Generic Drugs Faces Hurdles Like India’s Low-Cost Labor and” — what this page in the network covers. President Trump’s plan to bring generic drug manufacturing back to the United States faces significant obstacles, as illustrated by India’s dominance in the industry. India supplies about 40% of America’s generic drugs, thanks to cheap labor and established global supply chains that make U.S. Building new American factories would require billions in investment and years of construction, while Indian manufacturers already operate at massive scale with lower costs.
The reliance on India and China for active pharmaceutical ingredients means that even if final assembly returns to the U.S., the supply chain remains global. This matters because drug shortages have become a national security concern, but reshoring production could raise prices for consumers and strain federal budgets. This listing links straight to the original page, where the content is available in full.